[go: up one dir, main page]

AU2017374947A8 - New anti-angiogenic extracellular vesicles - Google Patents

New anti-angiogenic extracellular vesicles Download PDF

Info

Publication number
AU2017374947A8
AU2017374947A8 AU2017374947A AU2017374947A AU2017374947A8 AU 2017374947 A8 AU2017374947 A8 AU 2017374947A8 AU 2017374947 A AU2017374947 A AU 2017374947A AU 2017374947 A AU2017374947 A AU 2017374947A AU 2017374947 A8 AU2017374947 A8 AU 2017374947A8
Authority
AU
Australia
Prior art keywords
extracellular vesicles
new anti
angiogenic
evs
angiogenic extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2017374947A
Other versions
AU2017374947B2 (en
AU2017374947A1 (en
Inventor
Maurizio Muraca
Antonella Viola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Citta Della Speranza - Onlus
Universita degli Studi di Padova
Original Assignee
Fond Citta Della Speranza Onlus
Univ Degli Studi Padova
Universita degli Studi di Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Citta Della Speranza Onlus, Univ Degli Studi Padova, Universita degli Studi di Padova filed Critical Fond Citta Della Speranza Onlus
Publication of AU2017374947A1 publication Critical patent/AU2017374947A1/en
Publication of AU2017374947A8 publication Critical patent/AU2017374947A8/en
Application granted granted Critical
Publication of AU2017374947B2 publication Critical patent/AU2017374947B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses new aiiti-angiogenic extracellular vesicles (extracellular vesicles, EV) formed from stent/stromal mesenchymal cells (also known as mesenchymal stem cells, MSC), said EVs for the treatment of diseases characterized by an increased vascularisation, pharmaceutical compositions comprising the same and methods for the preparation of said EVs.
AU2017374947A 2016-12-14 2017-12-14 New anti-angiogenic extracellular vesicles Active AU2017374947B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2016/057608 WO2018109525A1 (en) 2016-12-14 2016-12-14 New anti-angiogenic extracellurlar vesicles
AUPCT/IB2016/057608 2016-12-14
PCT/IB2017/057928 WO2018109700A1 (en) 2016-12-14 2017-12-14 New anti-angiogenic extracellurlar vesicles

Publications (3)

Publication Number Publication Date
AU2017374947A1 AU2017374947A1 (en) 2019-08-01
AU2017374947A8 true AU2017374947A8 (en) 2020-01-16
AU2017374947B2 AU2017374947B2 (en) 2023-08-24

Family

ID=57755412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017374947A Active AU2017374947B2 (en) 2016-12-14 2017-12-14 New anti-angiogenic extracellular vesicles

Country Status (5)

Country Link
EP (1) EP3554513A1 (en)
CN (1) CN110312515B (en)
AU (1) AU2017374947B2 (en)
CA (1) CA3052739A1 (en)
WO (2) WO2018109525A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111548SA (en) * 2019-04-18 2021-11-29 Agency Science Tech & Res Composition
CN113384597A (en) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 Aerosol inhalation preparation containing human cell-derived extracellular vesicles, preparation method and application thereof
WO2021207025A1 (en) * 2020-04-06 2021-10-14 University Of Georgia Research Foundation, Inc Mesenchymal cell (msc) exosomes increase t cell differentiation towards t regulatory cells
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
KR102184428B1 (en) * 2020-05-25 2020-11-30 주식회사 씨케이엑소젠 Method for preparing exosomes from mesenchymal stem cells and culture solution and culture solution produced from the same
US20250186498A1 (en) * 2022-05-16 2025-06-12 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition for hearing loss mitigation and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
PL2254586T3 (en) * 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Mesenchymal stem cell particles
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
JP2016507550A (en) * 2013-02-12 2016-03-10 リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ Method for producing fine particles
PT3027738T (en) * 2013-08-01 2022-05-11 Swedish Stromabio Ab Mscs in the treatment of inflammatory pulmonary diseases
WO2015076717A2 (en) * 2013-11-21 2015-05-28 Isletone Ab Mscs in the treatment of cardiac disorders
CN105861430B (en) * 2016-04-29 2019-07-23 南京大学 A kind of preparation method of exosome and exosome and its application in preparing medicine or preparation for treating sepsis

Also Published As

Publication number Publication date
WO2018109700A1 (en) 2018-06-21
CN110312515A (en) 2019-10-08
AU2017374947B2 (en) 2023-08-24
EP3554513A1 (en) 2019-10-23
WO2018109525A1 (en) 2018-06-21
CA3052739A1 (en) 2018-06-21
CN110312515B (en) 2023-05-16
AU2017374947A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
AU2017374947A8 (en) New anti-angiogenic extracellular vesicles
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MY191581A (en) Anti-pd-1 antibodies
TW201613901A (en) New compounds
EP4306166A3 (en) Compounds, compositions and methods of use
MX369623B (en) Fused bicyclic compounds for the treatment of disease.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EP4527463A3 (en) Compositions and methods for the delivery of therapeutics
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MY193728A (en) Muscarinic receptor agonists
EP3342858A4 (en) Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12017500809B1 (en) Improved il-6 antibodies
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
PH12016501613A1 (en) Pyrazines modulators of gpr6
WO2019087130A3 (en) Method of inhibiting angiogenesis
MX2017010422A (en) Imidazolyl tricyclic enones as antioxidant iflammation modulators.
EP4413974A3 (en) Methods of treating ocular conditions
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
WO2016061555A3 (en) Novel small molecule anticancer agents
MX382092B (en) Heterocyclic compounds for the treatment of disease
IN2014CH00840A (en)
MX370897B (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 33 , NO 29 , PAGE(S) 4248 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME L'UNIVERSITA DEGLI STUDI DI PADOVA, APPLICATION NO. 2017374947, UNDER INID (71) CORRECT THE APPLICANT NAME TO UNIVERSITA DEGLI STUDI DI PADOVA

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NEW ANTI-ANGIOGENIC EXTRACELLULAR VESICLES

FGA Letters patent sealed or granted (standard patent)